Financial Performance - The company's operating revenue for 2022 was ¥2,966,656,380.11, representing a 1.03% increase compared to ¥2,936,304,792.98 in 2021[19] - The net profit attributable to shareholders for 2022 was ¥90,176,711.03, a decrease of 15.21% from ¥106,357,144.47 in 2021[19] - The net profit after deducting non-recurring gains and losses was ¥76,242,658.45, down 14.44% from ¥89,110,443.62 in the previous year[19] - The net cash flow from operating activities was negative at -¥27,273,965.48, a decline of 123.19% compared to ¥117,613,585.10 in 2021[19] - Basic earnings per share decreased by 14.29% to ¥0.36 from ¥0.42 in 2021[19] - Total assets at the end of 2022 reached ¥2,604,514,578.00, a significant increase of 59.04% from ¥1,637,617,535.07 in 2021[19] - The net assets attributable to shareholders rose by 109.14% to ¥1,586,106,872.49 from ¥758,397,541.67 in 2021[19] - The company achieved a total revenue of 2.967 billion yuan in 2022, representing a year-on-year growth of 1.05%, while the net profit attributable to shareholders decreased by 15.30% to 90 million yuan[58] - The internet digital marketing sector contributed ¥2,012,185,418.95, accounting for 67.83% of total revenue, with a growth of 4.20% from the previous year[68] - Revenue from the North China region surged by 78.82% to ¥1,638,774,048.16, significantly increasing its share of total revenue to 55.24%[68] - The gross profit margin for the internet digital marketing sector was 3.82%, reflecting a slight decrease of 0.52% compared to the previous year[70] - The gross profit margin for the printing and packaging supply chain business was 11.15%, with a year-on-year increase of 0.23%[70] - The company's total operating costs were ¥2,687,335,817.49, remaining stable compared to the previous year[74] - Revenue from overseas sales decreased by 34.43% to ¥12,202,298.82, indicating challenges in international markets[68] Investment and Capital Management - The company successfully issued 68.04 million new shares in December 2022, raising a total of 750 million yuan to enhance operational vitality and promote structural optimization[61] - The company is advancing the "Global Printing Expansion and Green Packaging Intelligent Manufacturing Industrial Park" project, which commenced in 2021, to support future smart, green, and digital factory implementations[60] - The company has committed to invest RMB 55 million in the expansion of its printing and green packaging smart manufacturing industrial park, with 19.47% of the investment completed as of the reporting period[102] - For the pharmaceutical packaging folding box expansion project, the company has committed RMB 25 million, with 28.37% of the investment completed[102] - The company raised a total of RMB 750,481,200.00 through a private placement of 68,040,000 shares at an issue price of RMB 11.03 per share, with a net amount of RMB 737,532,619.79 after deducting related issuance costs[101] - The company plans to use up to RMB 400 million of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months from the board's approval date[103] - The company has not engaged in any significant equity or non-equity investments during the reporting period[98][99] - The company has not utilized any idle raised funds for temporary working capital as of December 31, 2022[103] - As of December 31, 2022, the company had unused raised funds amounting to 100 million yuan, which will be allocated for subsequent investment projects[104] Research and Development - Research and development expenses amounted to ¥51,613,861.34, a decrease of 1.35% compared to the previous year[78] - The company has focused on technological innovation, particularly in drug packaging technology, enhancing product quality and production efficiency[80] - The company is increasing R&D investment to adapt to technological advancements in the packaging industry, focusing on automation and digitalization[137] - The company has obtained 25 new patents and 3 software copyrights during the reporting period, bringing the total to 205 intellectual property rights, including 130 patents and 75 software copyrights, maintaining its leading position in the industry[41] - The number of R&D personnel decreased by 12.09% from 215 in 2021 to 189 in 2022, with the proportion of R&D staff dropping from 19.37% to 17.76%[83] Market Strategy and Expansion - The company aims to expand its pharmaceutical packaging business, leveraging the projected 3%-6% annual growth rate of the global pharmaceutical market from 2022 to 2026[28] - The company is focusing on developing high-end packaging solutions for fast-moving consumer goods and health products, targeting mid to high-end markets[33] - The digital marketing segment is expected to grow as brands increasingly invest in digital marketing, with a focus on optimizing marketing effectiveness through data-driven strategies[31] - The company is actively pursuing the integration of the supply chain and innovating its business model to achieve transformation and upgrade based on traditional supply chain models[123] - The company plans to expand its internet digital marketing business by entering the live e-commerce sector and leveraging its digital marketing experience in the metaverse, focusing on virtual digital image creation and virtual idol IP operations[121] - The company is focusing on expanding its market presence through new product development and technological advancements in packaging solutions[82] - The company is committed to enhancing post-merger management to maximize synergies from acquisitions[144] Governance and Management - The company appointed Lei Yongquan as the new chairman on January 10, 2023, following the retirement of Li Yiling due to reaching the legal retirement age[166] - The current chairman, Lei Yongquan, has a background in finance and has held various senior positions in related companies since 2012[167] - The company has experienced a change in its board of directors, with Lei Yongquan being elected as chairman and Sun Xuejun continuing as general manager[166] - The management team consists of experienced professionals with backgrounds in finance, engineering, and management, contributing to the company's strategic direction[168] - The company is actively managing its governance structure to ensure effective oversight and strategic decision-making[166] - The company has a commitment to transparency, with detailed meeting resolutions published on the official information disclosure platform[183] - The board of directors held a total of 19 meetings during the reporting period, with resolutions disclosed on various dates[183] Employee and Compensation Policies - The total number of employees at the end of the reporting period was 1,064, with 571 in the parent company and 493 in major subsidiaries[193] - The company has implemented a performance-oriented compensation and performance management system to enhance employee motivation and skills[194] - The company emphasizes employee training as a key factor for talent development and performance improvement, with plans covering various dimensions such as safety, management, and technical skills[195] - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 5.456 million[180] - The independent directors received an annual salary of CNY 50,000 each (tax included) for the year 2022[180] Risk Management - The company recognizes the risks associated with national policy adjustments and plans to closely monitor policy directions to adapt its development goals and strategies accordingly[132] - The company faces risks from intensified industry consolidation and competition in the digital marketing sector, necessitating continuous improvement in its service capabilities[133] - The company is addressing the challenges of rapid scale expansion by optimizing internal processes and enhancing talent acquisition and training to mitigate management risks[136] - The company has a net accounts receivable of 451 million yuan, which poses a risk of bad debts if customer conditions deteriorate[143] - The company is facing risks from fluctuations in raw material prices, particularly industrial packaging paper, which could affect operating profits[140] Profit Distribution Policy - The profit distribution policy emphasizes continuity and stability, prioritizing cash dividends while considering sustainable development[196] - The company plans to distribute cash dividends of no less than 20% of the distributable profits for the next three years, provided there are no major investment plans or significant capital expenditures[198] - In a mature stage without major capital expenditures, the minimum cash dividend proportion should reach 80% of the profit distribution[198] - The company may conduct mid-term cash dividends based on profitability and funding needs, with specific plans approved by the board and shareholders[199]

Financial Performance - The company's operating revenue for Q1 2023 was ¥696,925,501.44, representing a 10.03% increase compared to ¥633,419,466.40 in the same period last year[4] - Net profit attributable to shareholders was ¥28,729,049.41, up 4.84% from ¥27,402,907.36 year-on-year[4] - Total operating revenue for Q1 2023 reached ¥696,925,501.44, an increase of 10% compared to ¥633,419,466.40 in Q1 2022[22] - The net profit for Q1 2023 was CNY 32,498,774.16, an increase of 1.79% compared to CNY 31,925,678.59 in Q1 2022[24] - The total comprehensive income attributable to the parent company was CNY 28,729,049.41, an increase from CNY 27,402,907.36 in the previous year[24] - The basic earnings per share remained stable at CNY 0.09, unchanged from Q1 2022[24] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥10,698,900.14, a decline of 141.46% compared to ¥25,807,505.26 in the previous year[4] - The cash flow from operating activities showed a net outflow of CNY -10,698,900.14, a significant decrease from the previous year's inflow of CNY 25,807,505.26[25] - The company reported a decrease in cash flow from operating activities, indicating potential challenges in cash generation[25] - The cash balance at the end of the reporting period is RMB 711,217,748.73, down from RMB 906,522,100.48 at the beginning of the year[19] - The cash and cash equivalents at the end of the period were CNY 682,889,219.70, down from CNY 233,565,112.62 at the end of Q1 2022[27] - The company incurred a cash outflow of CNY 73,790,814.76 in investment activities, compared to CNY 7,785,033.24 in the same period last year[27] - The cash flow from financing activities resulted in a net outflow of CNY -119,900,261.61, compared to CNY -61,006,303.84 in Q1 2022[27] Assets and Liabilities - Total assets decreased by 4.46% to ¥2,488,444,593.26 from ¥2,604,514,578.00 at the end of the previous year[4] - Accounts receivable increased to ¥546,801,168.93 from ¥451,360,796.25, showing a growth of about 21%[21] - Total liabilities decreased to ¥771,114,976.93 from ¥919,683,735.82, a decline of approximately 16.1%[21] - The company's equity attributable to shareholders increased by 1.81% to ¥1,614,835,921.90 from ¥1,586,106,872.49 at the end of the previous year[4] - The company's equity attributable to shareholders increased to ¥1,614,835,921.90 from ¥1,586,106,872.49, reflecting a growth of about 1.8%[21] Operational Metrics - Total operating costs amounted to ¥659,545,187.78, up from ¥601,879,022.53, reflecting a rise of approximately 9.6%[22] - The company incurred a credit impairment loss of ¥5,841,905.12, compared to a loss of ¥1,855,884.71 in the previous year[22] - Inventory decreased by 47.77% to ¥49,875,558.27, attributed to increased sales and reduced stocking[9] - Inventory decreased significantly to ¥49,875,558.27 from ¥95,500,351.74, a reduction of approximately 47.8%[21] - Research and development expenses were reported at ¥14,132,285.59, down from ¥16,502,638.89, a decrease of approximately 15.4%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,804[12] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds 36.42% of shares, totaling 116,550,000 shares[12] Investments and Projects - Cash paid for fixed asset purchases surged by 742.03% to ¥65,552,148.76, reflecting significant investments in key production equipment[10] - The company repaid bank loans amounting to ¥253,899,351.46, an increase of 89.16% compared to the previous year[10] - The company is constructing a green packaging smart manufacturing industrial park, which includes primary and secondary pharmaceutical packaging production centers and a technology R&D center[16] - The registered capital for the new materials project company in Tianjin is set to be no less than RMB 80 million, with a total investment of at least RMB 100 million[17] Other Information - The company maintained a stable capital reserve of ¥714,687,690.36, unchanged from the previous period[21] - The company has not disclosed any new product developments or market expansion strategies in this report[28]

投资者关系活动记录表 证券代码： 002799 证券简称：环球印务 西安环球印务股份有限公司 投资者关系活动记录表 编号：2017-002 | --- | --- | --- | |-------------------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动类 | □ | 媒体采访 □业绩说明会 | | 别 | □ □ 现场参观 | 新闻发布会 □路演活动 | | 参与单位名称 及人员姓名 | | □其他（请文字说明其他活动内容） 东北证券股份有限公司：唐凯 | | | | 北京市星石投资管理有限公司：王龙 | | 时间 | 2017 年 3 月 9 | 日 下午 14:00-16:00 | | 地点 公司接待人员 | 公司三楼证券投资部 ...

投资者关系活动记录表 1 证券代码： 002799 证券简称：环球印务 西安环球印务股份有限公司 投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |-----------------------------|-------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动类 | □ | 媒体采访 □业绩说明会 | | 别 | □ □ 现场参观 | 新闻 ...

投资者关系活动记录表 1 证券代码： 002799 证券简称：环球印务 西安环球印务股份有限公司 投资者关系活动记录表 编号：2017-004 | --- | --- | --- | |-----------------------------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

投资者关系活动记录表 1 证券代码： 002799 证券简称：环球印务 西安环球印务股份有限公司 投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |-------------------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动类 | □ | 媒体采访 □业绩说明会 | | 别 | □ □ 现场参观 | 新闻发布会 □路演活动 | | | | □其他（请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | | 国信证券股份有限公司：丰毅 | | 时间 | 2017 年 11 月 | 10 日 下午 14 ...

[Key Financial Data](index=2&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) [Core Financial Indicators](index=2&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In Q3 2022, operating revenue grew by **55.78%**, but net profit declined, with year-to-date net profit down **18.27%** despite a **4.06%** revenue increase, indicating profitability challenges Key Financial Data for Q3 2022 and Year-to-Date | Indicator | Current Period (Q3 2022) (CNY) | YoY Change (Current Period) | YTD (Q3 2022) (CNY) | YoY Change (YTD) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 1,063,676,865.47 | 55.78% | 2,401,523,534.17 | 4.06% | | Net Profit Attributable to Shareholders | 22,782,631.86 | -3.99% | 82,996,425.93 | -18.27% | | Net Cash Flow from Operating Activities | - | - | 54,425,322.06 | 17.95% | | Basic Earnings Per Share | 0.09 CNY/share | -18.18% | 0.33 CNY/share | -17.50% | | Total Assets (Period-End) | 1,830,833,597.44 | 11.80% (vs. Prior Year-End) | 1,830,833,597.44 | 11.80% (vs. Prior Year-End) | | Shareholders' Equity Attributable to Parent (Period-End) | 841,393,967.60 | 10.94% (vs. Prior Year-End) | 841,393,967.60 | 10.94% (vs. Prior Year-End) | [Non-Recurring Gains and Losses](index=2&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) Year-to-date, non-recurring gains and losses totaled **8.42 million CNY**, primarily from **12.10 million CNY** in government subsidies and tax incentives, effectively supplementing current profit Non-Recurring Gains and Losses Items for YTD 2022 | Item | Amount (CNY) | Description | | :--- | :--- | :--- | | Government subsidies included in current profit/loss | 12,098,258.94 | Receipt of government subsidies and tax incentives | | Non-current asset disposal gains/losses | -7,258.83 | Loss from disposal of fixed assets | | **Total** | **8,419,934.40** | -- | [Shareholder Information](index=3&type=section&id=%E4%BA%8C%E3%80%81%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) [Shareholding Structure](index=3&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) As of the reporting period end, the company had **16,350** common shareholders, with the top two holding **46.25%** and **16.15%** respectively, indicating a relatively concentrated equity structure - As of the reporting period end, the company's total number of common shareholders was **16,350**[9](index=9&type=chunk) Top Two Shareholders' Shareholding | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares | | :--- | :--- | :--- | :--- | | Shaanxi Pharmaceutical Holdings Group Co., Ltd. | State-owned Legal Person | 46.25% | 116,550,000.00 | | Hong Kong Yuanshi International Co., Ltd. | Overseas Legal Person | 16.15% | 40,704,440.00 | - Some of the top ten shareholders have related party relationships: Shanghai Jiangnan Architectural Planning Consulting Co., Ltd. is a wholly-owned subsidiary of Shanghai Jiangnan Architectural Design Institute (Group) Co., Ltd., and Jin Jun is a director of the latter[10](index=10&type=chunk) [Other Significant Matters](index=4&type=section&id=%E4%B8%89%E3%80%81%E5%85%B6%E4%BB%96%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) [Progress on Major Projects](index=4&type=section&id=1%E3%80%81%E7%8E%AF%E7%90%83%E5%8D%B0%E5%8A%A1%E6%89%A9%E4%BA%A7%E6%9A%A8%E7%BB%BF%E8%89%B2%E5%8C%85%E8%A3%85%E6%99%BA%E8%83%BD%E5%88%B6%E9%80%A0%E5%B7%A5%E4%B8%9A%E5%9B%AD%E9%A1%B9%E7%9B%AE) The "Global Printing Expansion and Green Packaging Smart Manufacturing Industrial Park Project" is progressing, with an engineering general contract signed, aiming to expand pharmaceutical packaging capacity and establish an R&D center - The company's "Green Packaging Smart Manufacturing Industrial Park Project" in Xixian New Area Airport New City is proceeding normally, encompassing primary and secondary pharmaceutical packaging production centers and a technology R&D center[10](index=10&type=chunk) - During the reporting period, the company's wholly-owned subsidiary Lingfeng Global signed a "Construction Project General Contract" with China Construction Fourth Engineering Division Corp., Ltd., moving the project into a substantive construction phase[10](index=10&type=chunk) [Refinancing Plan](index=4&type=section&id=2%E3%80%81%E9%9D%9E%E5%85%AC%E5%BC%80%E5%8F%91%E8%A1%8C%20A%20%E8%82%A1%E8%82%A1%E7%A5%A8%E4%BA%8B%E9%A1%B9) The non-public issuance of A-shares, approved by the CSRC, plans to issue up to **68,040,000** shares to no more than 35 specific investors, and is currently being advanced for opportunistic issuance - The company's application for non-public issuance of A-shares was approved by the China Securities Regulatory Commission (CSRC) on March 2, 2022 (CSRC Permit [2022] No. 397)[11](index=11&type=chunk) - The company plans to issue no more than **68,040,000** shares and is currently proceeding with the issuance, which will be executed opportunistically within the validity period[11](index=11&type=chunk) [Major Shareholder Reduction Plan](index=5&type=section&id=4%E3%80%815%25%E4%BB%A5%E4%B8%8A%E8%82%A1%E4%B8%9C%E5%87%8F%E6%8C%81%E4%BA%8B%E9%A1%B9) Major shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to **6%** of total share capital within six months, potentially impacting share price - Shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its holdings by no more than **15,120,000** company shares, representing **6%** of the company's total share capital[14](index=14&type=chunk) [Quarterly Financial Statements](index=6&type=section&id=%E5%9B%9B%E3%80%81%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) [Consolidated Balance Sheet Analysis](index=6&type=section&id=1%E3%80%81%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of Sep 30, 2022, total assets were **1.83 billion CNY**, up **11.80%** from year-start, with liabilities at **894.92 million CNY**; significant increases in prepayments, short-term borrowings, and contract liabilities reflect business expansion and increased advance receipts Balance Sheet Key Item Changes (Sep 30, 2022 vs Jan 1, 2022) | Item | Period-End Balance (CNY) | Year-Start Balance (CNY) | Change | | :--- | :--- | :--- | :--- | | **Total Assets** | **1,830,833,597.44** | **1,637,617,535.07** | **+11.80%** | | Prepayments | 436,814,008.85 | 154,366,910.40 | +182.98% | | **Total Liabilities** | **894,921,659.65** | **793,088,893.48** | **+12.84%** | | Short-term Borrowings | 339,833,395.93 | 232,118,875.75 | +46.40% | | Contract Liabilities | 114,208,148.15 | 10,957,078.63 | +942.31% | | **Total Equity Attributable to Parent Company Owners** | **841,393,967.60** | **758,397,541.67** | **+10.94%** | [Consolidated Income Statement Analysis](index=8&type=section&id=2%E3%80%81%E5%90%88%E5%B9%B6%E5%B9%B4%E5%88%9D%E5%88%B0%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E5%88%A9%E6%B6%A6%E8%A1%A8) In Q1-Q3 2022, operating revenue reached **2.40 billion CNY**, up **4.06%**, but higher cost growth and a sharp decline in investment income led to a **23.09%** drop in operating profit and an **18.27%** decline in net profit, indicating profitability pressure Income Statement Key Item Changes (Q1-Q3 2022 vs Q1-Q3 2021) | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | YoY Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 2,401,523,534.17 | 2,307,918,790.20 | +4.06% | | Operating Cost | 2,171,219,418.50 | 2,061,101,044.24 | +5.34% | | Investment Income | 2,581,851.90 | 13,990,821.86 | -81.55% | | Operating Profit | 104,724,011.82 | 136,155,442.35 | -23.09% | | Net Profit Attributable to Parent Company Shareholders | 82,996,425.93 | 101,549,331.34 | -18.27% | [Consolidated Cash Flow Statement Analysis](index=9&type=section&id=3%E3%80%81%E5%90%88%E5%B9%B6%E5%B9%B4%E5%88%9D%E5%88%B0%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) In Q1-Q3 2022, net cash flow from operating activities was **54.43 million CNY**, up **17.95%**, while investment and financing activities resulted in net outflows, leading to a decrease in cash and cash equivalents Cash Flow Statement Key Items (Q1-Q3 2022) | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 54,425,322.06 | 46,144,103.80 | | Net Cash Flow from Investing Activities | -50,296,585.80 | -97,479,777.32 | | Net Cash Flow from Financing Activities | -53,296,378.38 | 16,322,547.83 | | Net Increase in Cash and Cash Equivalents | -49,167,642.12 | -35,013,125.69 |

Financial Performance - The company reported a revenue of CNY 1,337,846,668.70 for the first half of 2022, a decrease of 17.68% compared to CNY 1,625,130,768.07 in the same period last year[20]. - Net profit attributable to shareholders was CNY 60,213,794.07, down 22.62% from CNY 77,818,940.60 year-on-year[20]. - Basic and diluted earnings per share decreased to CNY 0.24, down 22.58% from CNY 0.31 in the same period last year[20]. - The company's operating revenue for the reporting period was ¥1,337,846,668.70, a decrease of 17.68% compared to ¥1,625,130,768.07 in the same period last year[67]. - The company's operating costs decreased by 18.68% to ¥1,180,903,132.68 from ¥1,452,150,021.94 year-on-year[67]. - The net profit for the first half of 2022 was CNY 68,920,718.90, a decrease from CNY 92,101,232.11 in the first half of 2021, which is a decline of around 25.14%[185]. - The total profit for the first half of 2022 was CNY 73,924,199.72, down from CNY 104,923,398.90 in the first half of 2021, reflecting a decline of about 29.54%[184]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to CNY 35,540,255.46, a rise of 3,578.23% compared to CNY 966,233.16 in the previous year[20]. - The company reported a net increase in cash and cash equivalents of ¥7,450,861.59, compared to a decrease of ¥31,616,747.42 in the previous year[67]. - Cash and cash equivalents at the end of the reporting period were ¥305,141,629.07, a slight decrease of 0.85% from ¥299,361,975.03[72]. - The total cash inflow from financing activities was CNY 361,549,956.32, compared to CNY 264,323,567.81 in the previous year, reflecting a 37% increase in financing efforts[190]. - The total cash and cash equivalents at the end of the period increased to CNY 283,581,140.29 from CNY 260,444,662.53, marking a positive change in liquidity[190]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,750,462,739.97, reflecting a growth of 6.89% from CNY 1,637,617,535.07 at the end of the previous year[20]. - Current liabilities rose to CNY 802,670,111.71, up from CNY 741,040,523.41, indicating an increase of 8.5%[179]. - Non-current liabilities decreased to CNY 34,343,267.77 from CNY 52,048,370.07, a reduction of 34.0%[179]. - The total balance of restricted assets at the end of the reporting period was ¥22,145,241.14, down from ¥26,532,891.77 at the end of the previous year[4]. Research and Development - Research and development investment increased by 10.12% to ¥28,385,361.25 from ¥25,777,866.63 year-on-year[67]. - The company is increasing its research and development investments to keep pace with technological advancements in automation and artificial intelligence[96]. - The company has obtained 18 new patents and 3 software copyrights during the reporting period, with a total of 161 intellectual property rights, maintaining its leading position in the industry[47]. Market Position and Strategy - The company ranks 15th in the "2022 Top 100 Printing and Packaging Enterprises in China" list, indicating its leading position in the pharmaceutical packaging sector[36]. - The company is focusing on expanding its pharmaceutical packaging business, particularly in the chemical drug market, ensuring the achievement of operational goals[31]. - The company aims to maintain stable growth in the pharmaceutical packaging sector while exploring new business models in digital marketing and supply chain management[36]. - The company is actively developing high-end packaging for fast-moving consumer goods, health products, and cosmetics, targeting well-known domestic and international clients[37]. Environmental and Social Responsibility - The company emphasizes safety and environmental protection, implementing strict safety management and training programs[34]. - The company has established two sets of organic waste gas treatment facilities, which are operating well without any abnormalities during the reporting period[111]. - The company is committed to social responsibility, providing educational subsidies to two employees to enhance their skills[117]. - The company has implemented measures to reduce carbon emissions, although specific results were not detailed in the report[116]. Corporate Governance - The company has maintained stable governance with no changes in its board or management during the reporting period[106]. - The controlling shareholder, Shaanxi Medical Holdings Group, holds a 65% stake in the company and has made commitments to avoid related party transactions[121]. - The company has committed to ensuring that any necessary transactions with related parties will adhere to market principles and fair pricing[121]. Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue streams[183]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[195].

西安环球印务股份有限公司 2022 年第一季度报告 证券代码：002799 证券简称：环球印务 公告编号：2022-022 西安环球印务股份有限公司 2022年第一季度报告 本公司及全体董事保证本公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 重要内容提示: 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务 信息的真实、准确、完整。 3、第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部分） | -980.77 | 处置固定资产损失 | | 计入当期损益的政府补助（与公司正常经营业务密切相关， 符合国家政策规定、按照一定标准定额或定量持续享受的政 府补助除外） ...

Financial Performance - The company's operating revenue for 2021 was approximately ¥2.94 billion, representing a 56.57% increase compared to ¥1.88 billion in 2020[19]. - The net profit attributable to shareholders for 2021 was approximately ¥106.36 million, a 5.00% increase from ¥101.29 million in 2020[19]. - The net cash flow from operating activities improved significantly to approximately ¥117.61 million, a 364.47% increase from a negative cash flow of ¥44.47 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥1.64 billion, reflecting a 9.21% increase from ¥1.50 billion at the end of 2020[19]. - The net assets attributable to shareholders increased by 13.26% to approximately ¥758.40 million at the end of 2021, up from ¥669.61 million at the end of 2020[19]. - The basic earnings per share for 2021 was ¥0.42, a 5.00% increase from ¥0.40 in 2020[19]. - The weighted average return on equity for 2021 was 14.89%, a slight decrease of 0.74% from 15.63% in 2020[19]. - The company reported a decrease of 3.79% in net profit after deducting non-recurring gains and losses, totaling approximately ¥89.11 million in 2021 compared to ¥92.62 million in 2020[19]. Market Position and Growth - The company ranked 20th in the "2021 Top 100 Printing and Packaging Enterprises in China" list, highlighting its leading position in the pharmaceutical packaging sector[36]. - The company maintains stable growth in the pharmaceutical packaging sector, with established partnerships with major pharmaceutical companies including Bayer, Johnson & Johnson, and Novartis[36]. - The company aims to expand its market presence beyond China, targeting regions such as Hong Kong, Japan, and Southeast Asia[36]. - The pharmaceutical packaging industry is expected to maintain stable profit levels, despite fluctuations in raw material prices impacting overall profitability[31]. - The pharmaceutical packaging market is projected to grow from $111 billion in 2021 to $118 billion by 2026, with a compound annual growth rate of 8.24%[134]. Research and Development - The company has developed a blockchain-based traceability management system for pharmaceuticals and consumer goods, integrating modern technologies like 5G and IoT[41]. - The company is focusing on enhancing product quality and processing efficiency through innovations in drug packaging technology[88]. - The company's R&D investment amounted to ¥82,223,343.90 in 2021, representing a 46.77% increase from ¥56,021,167.75 in 2020[92]. - R&D personnel increased to 215 in 2021, up 17.49% from 183 in 2020, with R&D personnel accounting for 19.37% of the total workforce[92]. - The company is committed to increasing R&D investment to keep pace with technological advancements and ensure continuous improvement in products and services[150]. Strategic Initiatives - The company has initiated a green packaging intelligent manufacturing project, investing nearly CNY 100 million in land purchase and preliminary design[68]. - The company is entering the live e-commerce sector and exploring digital marketing in the metaverse, focusing on virtual digital image creation and virtual idol IP operations[139]. - The company plans to leverage capital market financing to support capacity expansion and intelligent upgrades in Xi'an and Tianjin, enhancing its product line and service efficiency[138]. - The company aims to implement a C2M supply chain model, providing collaborative management services from raw materials to consumers[144]. Corporate Governance - The company has established a robust corporate governance structure, holding 9 board meetings and 8 supervisory meetings to ensure compliance with legal requirements[164][165]. - The company emphasizes transparency and timely information disclosure to protect shareholders' rights and enhance corporate governance[168]. - The company maintains independence from its controlling shareholder in business operations, personnel, assets, and finances, ensuring no non-operating fund transfers occurred during the reporting period[163]. - The company has a fully independent human resources department, managing personnel matters without interference from shareholders[173]. Risks and Challenges - The company has indicated potential risks in its future development outlook, which investors should be aware of[4]. - The company faces risks from national policy changes affecting the pharmaceutical and consumer goods sectors, and it will adapt its strategies accordingly[145]. - The company is facing risks from fluctuations in raw material prices, particularly in industrial packaging paper, which could impact sales revenue if costs rise significantly[153]. - The company has implemented strict sales collection policies to reduce the proportion of accounts receivable to operating income, thereby improving cash flow[154].